GSK Signs US$1.4 B ADC Option Deal with Mersana
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 8 (Table of Contents)
Published: 17 Aug-2022
DOI: 10.3833/pdr.v2022.i8.2717 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Looking to build its presence within the ADC space, GSK has entered into an option agreement with Mersana Therapeutics to co-develop and commercialise the latter’s candidate, XMT-2056...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS